1.52 BILCAP & DOACs for Thromboprophylaxis in Patients with Cancer with Dr. Sven Olson
In this week's episode we critique the statistics…
Plenary Session - inactive due to federal service · Plenary Session - inactive due to federal service
April 4, 201959m 37sExplicit
Audio is streamed directly from the publisher (feeds.soundcloud.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
In this week's episode we critique the statistics of the recent trial "Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study" that was published in The Lancet Oncology. Then, with Dr. Sven Olson of OHSU, we break down the two papers published in NEJM on thromboprophylaxis with direct oral anticoagulants (DOACs) for patients with cancer: "Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer" and "Apixaban to Prevent Venous Thromboembolism in Patients with Cancer".
BILCAP: www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30915-X
Rivaroxaban: doi.org/10.1056/NEJMoa1814630
Apixaban: doi.org/10.1056/NEJMoa1814468
Back us on Patreon! www.patreon.com/plenarysession
Topics
medicineoncologyhealthpolicy